Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Tigenix AlloCSC 01 stem cell therapy AMI

News and Trends 13 Mar 2017

New Cardiac Stem Cell Therapy passes Phase I/II Trials

TiGenix announces positive one-year results for its phase I/II trial of donor-derived cardiac stem cell therapy in acute myocardial infarction (AMI). The Belgian biotech TiGenix is developing allogeneic stem cell therapies. Now the company has announced that its cardiac stem cell therapy AlloCSC-01 reached its primary endpoints in a phase I/II trial. In 2015, the company acquired Coretherapix in a €292M deal for its allogeneic cardiac stem […]

March 13, 2017 - 3 minutesmins - By Melanie De Almeida

tanya may 2

News and Trends 13 Mar 2017

This Dutch Company is Upgrading ADCs for Immunotherapy

T-Guard is CEO and co-founder Ypke van Oosterhout’s life work. He told us about the technology that he has been developing since his graduate studies. It was during his post-MSc research that Ypke van Oosterhout ‘discovered’ T-Guard, a technology which neutralizes rogue T cells. Seeing its clinical potential, Oosterhout took the concept and ran with it — […]

March 13, 2017 - 7 minutesmins - By External Contributor

venars.original

Interview 13 Mar 2017

Meet the Omics Entrepreneur who also Co-Founded EMBL

If you haven’t heard of Kai Simons, his mile-long list of accomplishments will make you wonder why. He told us some of what he learned along the way. Our Head of Business Development, Tom, was on the train from Paris to Lille for an intense day of sales meetings when he pulled up the bio […]

March 13, 2017 - 7 minutesmins - By Evelyn Warner

oxford fleming penicillin exhibition

News and Trends 11 Mar 2017

You Can Watch Fleming’s Original Penicillin Culture in Oxford!

The Museum of the History of Science in Oxford is hosting an exhibition on the history of penicillin and the current challenges of antibiotic resistance featuring the first culture used to extract the antibiotic. The discovery of penicillin by Alexander Fleming in the early 20th century changed the world of medicine. Antibiotics have saved millions […]

March 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Galapagos Pharnext drug combination

News and Trends 10 Mar 2017

Galapagos finds a Partner to Boost its Pipeline with Drug Combinations

Galapagos and Pharnext will work together to develop low-dose drug combinations that improve drug efficacy and target new indications. Galapagos, the biggest biotech in Belgium, has closed an R&D agreement with the French Pharnext to develop drug combinations of the billion-euro biotech’s drug candidates with already approved drugs. While Pharnext’s focus has been neurodegenerative diseases, the […]

March 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

biofuel fas enzyme synbio chalmers

News and Trends 10 Mar 2017

SynBio Success with Enzyme opens Jet Fuel Production Possibilities

The well-known but stubborn FAS enzyme has been successfully modified to make petrol and jet fuel. This research opens up possibilities to produce biofuels with engineered microorganisms, or “cell factories”. Researchers from Chalmers University of Technology in Sweden have developed a method to modify the enzyme fatty acid synthase (FAS). This complex enzyme has long been […]

March 10, 2017 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

Research Integrin beta 3 cellular senescence

More News! 9 Mar 2017

There’s a New Target for Anti-Aging Therapies

According to a study at Queen Mary University of London (QMUL) published in the journal Cell Reports, the protein integrin-ß3 is a new marker and regulator of cellular senescence. Past research has revealed that the rising number of senescent cells, which appear during normal ageing, contributes to many age-related diseases. In a new study by Ana O’Loghlen and collegues, integrin-ß3 has been identified as […]

March 9, 2017 - 3 minutesmins - By Melanie De Almeida

hareluya

News and Trends 9 Mar 2017

Even if you don’t like IP, here’s Why Biotech Should Care about It

Biotech is renowned for its huge profits; but these would be nonexistent without intellectual property. What is the role of IP law in the industry? There is yet no other industry sector in which IP plays such an important role as in biotech, life sciences and pharma. The development of a new drug is a costly matter […]

March 9, 2017 - 4 minutesmins - By External Contributor

Top Selling Drugs 2016 Europe

Best in Biotech 8 Mar 2017

Which European Blockbusters Topped the Charts in 2016?

Blockbuster drugs are raking in billions each year in sales. Let’s have a look at the top 7 European best-seller drugs of 2016 and what their competition has to say. Not surprisingly, the top 3 best-selling drugs in Europe are biologicals, which are revolutionizing the treatment possibilities for a range of conditions, from cancer to chronic diseases. But with the increasing […]

March 8, 2017 - 4 minutesmins - By Melanie De Almeida

breath therapeutics sofinnova fundraising

News and Trends 8 Mar 2017

German Biotech closes Largest Series A Fundraising of 2017 So Far

Breath Therapeutics has raised €43.5M that will be used to finalize development and launch a therapy to improve survival in lung transplant patients. Sofinnova Partners, one of the top biotech VCs in Europe, and the Belgian Gimv have co-led the Series A round of Breath Therapeutics, a German company focusing on treating pulmonary orphan indications. […]

March 8, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 590679653

Interview 8 Mar 2017

International Women’s Day: An Infographic on Gender Diversity in Biotech

Today we celebrate women and promote a more gender-inclusive industry. Biotech is infamous for its divide, but what are the numbers? Whether it’s launching the next generation of insulin or running the business arm of one of Europe’s leading immuno-oncology biotechs, women have made major strides in biotechnology as some prominent leaders on the scene. “I […]

March 8, 2017 - 3 minutesmins - By Evelyn Warner

shutterstock 553640479

More News! 7 Mar 2017

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […]

March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT